A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Prasugrel (Primary)
- Indications Embolism and thrombosis; Sickle cell anaemia; Vaso-occlusive crisis
- Focus Registrational; Therapeutic Use
- Acronyms DOVE; TADO
- Sponsors Eli Lilly and Company
- 27 Jul 2020 This trial is completed in UK (Global End Date: 16 Sep 2015), according to European Clinical Trials Database record.
- 12 Dec 2017 Results of evaluation of candidate gene variants and impact of these variants on prasugrel treatment response presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2016 Results published in the Thrombosis and Haemostasis